NEW YORK, October 21, 2016 /PRNewswire/ --
Revenue in the U.S. Medical Instruments and Supplies space is forecasted to continue growing in the coming years due to favorable demographic and technological trends. Through 2021, the segment's industry value added (IVA) is anticipated to rise at an annualized rate of 1.0%. Pre-market, Stock-Callers.com reviews the most recent performances of Hill-Rom Holdings Inc. (NYSE: HRC), Waters Corp. (NYSE: WAT), Halyard Health Inc. (NYSE: HYH), and West Pharmaceutical Services Inc. (NYSE: WST). Learn more about these stocks by downloading their free report at:
Chicago, Illinois headquartered Hill-Rom Holdings Inc.'s stock finished Thursday's session at $59.64, rising 0.20%. A total volume of 172,042 shares was traded. Over the previous three months and since the start of this year, the Company's shares have gained 15.74% and 25.34%, respectively. The stock is trading above its 50-day and 200-day moving averages by 0.14% and 15.19%, respectively. Moreover, shares of Hill-Rom Holdings, which operates as a medical technology company worldwide, have a Relative Strength Index (RSI) of 45.37.
On September 28th, 2016, Hill-Rom Holdings announced its commitment to add over 100 new jobs at its Welch Allyn subsidiary's facilities in Skaneateles Falls, NY. The commitment, which will bring additional manufacturing, marketing and research, and development jobs to the area, comes one year after Hill-Rom acquired Welch Allyn, which is based in Central New York and has maintained a significant presence here for more than 100 years. The free research report on HRC is available at:
Shares in Milford, Massachusetts-based Waters Corp. ended yesterday's session 0.06% lower at $157.19 with a total trading volume of 464,117 shares. The stock has gained 0.30% in the past month, 5.21% in the previous three months, and 16.80% on an YTD basis. The Company's shares are trading 12.47% above their 200-day moving average. Moreover, shares of Waters, which operates as an analytical instrument manufacturer in the US and internationally, have an RSI of 48.93.
On October 4th, 2016, Waters Corp. announced that it would webcast its Q3 2016 financial results conference call live on October 25th at 8:00 a.m. ET. The complimentary report on WAT can be downloaded at:
On Thursday, Alpharetta, Georgia headquartered Halyard Health Inc.'s stock rose 0.29%, to close the day at $34.18. A total volume of 164,759 shares was traded. The Company's shares have advanced 1.88% in the previous three months and 2.30% on an YTD basis. The stock is trading 10.13% above its 200-day moving average. Additionally, shares of Halyard Health, which provides health and healthcare supplies and solutions worldwide, have an RSI of 45.88.
On October 19th, 2016, Halyard Health announced that it would webcast its conference call discussing financial results and business highlights for Q3 2016 on November 2nd, 2016 at 9 a.m. ET. The company will issue a news release detailing Q3 results before the market opens that same day. The conference call will be hosted by Robert Abernathy, chairman and chief executive officer, and Steve Voskuil, chief financial officer. Visit us today and download our complete research report on HYH for free at:
Shares in Exton, Pennsylvania headquartered West Pharmaceutical Services Inc. ended the day 0.33% lower at $72.49. A total volume of 221,128 shares was traded. The stock has gained 21.24% since the start of this year. The Company's shares are trading above their 200-day moving average by 2.05%. Furthermore, shares of West Pharmaceutical Services, which develops, manufactures, and sells packaging and delivery systems in the US, Germany, France, Other European countries, and internationally, have an RSI of 36.73.
On September 21st, 2016, research firm Wells Fargo downgraded the Company's stock rating from 'Outperform' to 'Market Perform'.
On September 26th, 2016, West Pharmaceutical Services announced it has appointed David A. Montecalvo to serve as Senior Vice President, Global Operations and Supply Chain, effective September 26, 2016. Mr. Montecalvo will serve on the senior leadership team and will oversee the Company's Global Operations function. Mr. Montecalvo joins West from Medtronic PLC, where he served in a number of senior leadership roles, including Vice President, Contract Manufacturing Operations, for the company's Restorative Therapies Group, a $7 billion group of businesses; and Vice President, Business Operations Integration, where he was responsible for directing and leading the global operations integration of Covidien plc into Medtronic. With 30 years of experience in the medical device and life science industry, Mr. Montecalvo has also held senior operations and product development roles at Urologix, Inc. and Lectec Corporation. Get free access to your technical report on WST at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA